Intuitive Surgical: The Gap Between Record Deliveries and a 35% Share Price Slide

Intuitive Surgical beats Q2 estimates but stock falls 35% YTD on weak procedure guidance and J&J's FDA-cleared OTTAVA rival, signaling end of monopoly era.

There is an unusual disconnect playing out at Intuitive Surgical right now. The company is shipping robots at a record pace, beating earnings estimates, and building new factories on the other side of the world — yet its stock has lost more than a third of its value since January. The market, it seems, is looking past the operational strength and focusing on something else entirely.

The Numbers Tell One Story

The second quarter of 2026 was, on paper, a strong one. Revenue came in at $2.89 billion, up 18.4 percent year over year, while earnings per share of $2.80 cleared analyst forecasts. System deliveries reached 468 units against a consensus estimate of 444 — a meaningful beat that suggests hospitals are still writing big checks for robotic surgery technology.

But here's where the narrative gets complicated. While the headline figures impressed, the company's guidance for future procedure growth — the metric that drives recurring revenue from instruments and accessories — did not fully satisfy investor expectations. That shortfall in forward-looking optimism appears to have weighed more heavily on the share price than the quarterly beat.

The stock closed recently at €316.35, a staggering 39 percent below its 52-week high of €516.50, which was reached as recently as January. Year to date, the shares are down 35 percent, trading well beneath the 50-day moving average of €336.34.

A Rival Finally Arrives

Part of the market's caution stems from a development that would have seemed unthinkable a decade ago: Johnson & Johnson has secured FDA De Novo clearance for its OTTAVA robotic surgical system. For years, competitors circled Intuitive's da Vinci franchise without ever truly threatening its quasi-monopoly. That era of unchallenged dominance now appears to be ending.

The timing is notable. The FDA approval arrived alongside the second-quarter results, creating a one-two punch that good earnings alone couldn't offset. The story of an insurmountable competitive moat — one that had underpinned the stock's valuation for years — is showing cracks.

Building for the Next Wave

Meanwhile, the company is making a strategic bet that its future growth will come from Asia. On August 19, Intuitive announced plans for a new manufacturing facility in Penang, Malaysia, covering 316,000 square feet under a lease agreement with the Penang Development Corporation. Operations are slated to begin in 2028, with 1,200 jobs expected to be created by 2032.

This represents a significant shift for a company that has historically concentrated its production in California. The move signals a recognition that the next wave of demand for surgical robotics is likely to emerge from Asian markets, and that supply chains need to be positioned accordingly.

Analyst Divergence and Insider Activity

Wall Street is clearly split on the stock's prospects. Oppenheimer upgraded Intuitive Surgical from "Perform" to "Outperform" on August 12, setting a price target of $500 and citing the company's advantageous positioning against slower-moving competitors. Since that call, however, the stock has fallen roughly 9 percent — a reminder of how little a single bullish voice can do against broader market sentiment.

Taking the opposite view, Wall Street Zen downgraded the stock from "Buy" to "Hold" in mid-August. This ambivalence reflects the broader uncertainty surrounding competitive threats, regulatory issues, and the sustainability of growth rates.

Adding another layer of complexity, several executives have been selling shares. Director Gary S. Guthart disposed of 10,000 shares at an average price of $400.00, while Amy L. Ladd and Gary Loeb also sold smaller packages. These transactions were conducted under Rule 10b5-1 automated trading plans — pre-arranged schedules designed to avoid any appearance of insider trading — with Guthart's plan running through June 2027. While routine in structure, the sales add to the narrative of caution around the stock.

Institutional interest tells a somewhat different story. Bank of New York Mellon recently established a new position of 3.36 million shares valued at approximately $1.34 billion, while Ally Financial Inc. and the Trust Co. of Vermont have also built or increased their holdings.

Governance and Regulatory Headwinds

The company has also been quietly updating its corporate governance. In late July, Intuitive revised its bylaws, partly in response to SEC requirements regarding universal proxy cards and disclosure obligations for shareholder nominations. This technical adjustment reflects a broader shift toward greater scrutiny of governance issues, particularly as institutional investors gain more weight in the shareholder structure.

Less visible but potentially significant are voluntary Class II recalls initiated by the FDA concerning certain components of the da Vinci SP system — specifically instrument arm covers and a part designated as Da Vinci ASSY PSS SP1098. The recalls relate to potential detachment issues or problems with retaining pins that could cause delays or safety risks. For a company whose entire business model rests on the trust of surgeons and hospitals in the reliability of its technology, such notices carry weight beyond their immediate operational impact.

The Central Question

Is Intuitive Surgical a company in transition, or one simply defending its dominance? The answer likely lies somewhere in between. The Malaysian factory expansion suggests management is thinking in terms of decades, not quarters. The delivery numbers suggest demand remains robust. But the share price tells a story of investors grappling with genuine competition for the first time, governance questions, and the perennial risk that comes with any recall, however voluntary.

The stock's slide from its January peak — a decline of roughly 35 percent since the start of the year — reflects a market that is no longer willing to grant the company the benefit of the doubt it once enjoyed. The question now is whether the operational momentum can eventually close the gap between what the company is achieving and what its share price is saying.